Patents by Inventor James Pottala

James Pottala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200400672
    Abstract: The present invention provides compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of ANGTPL4, DKK1, EPHA2, LAMC2, SPON2, SSR2, GAL1, GFRA1, LRRC15, CD147, CD320, CDH3, LRP10, SPINT2, SUSD2, and CST2, and their use in detecting breast cancer or disease recurrence.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 24, 2020
    Inventors: Kristi EGLAND, Rick EVANS, James POTTALA
  • Publication number: 20180275129
    Abstract: The present invention provides compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of ANGTPL4, DKK1, EPHA2, LAMC2, SPON2, SSR2, GAL1, GFRA1, LRRC15, CD147, CD320, CDH3, LRP10, SPINT2, SUSD2, and CST2, and their use in detecting breast cancer or disease recurrence.
    Type: Application
    Filed: June 7, 2018
    Publication date: September 27, 2018
    Inventors: Kristi EGLAND, Rick EVANS, James POTTALA
  • Patent number: 10001484
    Abstract: The present invention provides compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of ANGTPL4, DKK1, EPHA2, LAMC2, SPON2, SSR2, GAL1, GFRA1, LRRC15, CD147, CD320, CDH3, LRP10, SPINT2, SUSD2, and CST2, and their use in detecting breast cancer or disease recurrence.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: June 19, 2018
    Assignee: Sanford Health
    Inventors: Kristi Egland, Rick Evans, James Pottala
  • Publication number: 20150268241
    Abstract: The present invention provides compositions including reagents for detecting human autoantibodies against at least two proteins selected from the group consisting of ANGTPL4, DKK1, EPHA2, LAMC2, SPON2, SSR2, GAL1, GFRA1, LRRC15, CD147, CD320, CDH3, LRP10, SPINT2, SUSD2, and CST2, and their use in detecting breast cancer or disease recurrence.
    Type: Application
    Filed: March 17, 2015
    Publication date: September 24, 2015
    Inventors: Kristi EGLAND, Rick EVANS, James POTTALA
  • Publication number: 20140274891
    Abstract: This application relates to methods of predicting susceptibility or likelihood of a clinically-relevant mannose-binding lectin (MBL)-deficient subject to develop a cardiovascular disease and/or cardiodiabetes. The methods include measuring MBL mass or concentration and, optionally, measuring MBL activity, at least one other biomarker and/or genotyping of MBL gene and its promoters; combining the information obtained into a calculated MBL-inclusive index score that involves mathematical transformation; and assigning a risk of cardiadiabetic status and clinical endpoints based on the determination and comparison of the MBL inclusive index to reference values from a population.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: Health Diagnostic Laboratory, Inc.
    Inventors: Rebecca E. Caffrey, James Pottala, Stephen Varvel